Biocept (FRA:B00) Stock Based Compensation : €1.35 Mil (TTM As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biocept Stock Based Compensation?

Biocept's Stock Based Compensation for the three months ended in Jun. 2023 was €0.19 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 was €1.35 Mil.

Biocept Stock Based Compensation Historical Data

The historical data trend for Biocept's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Stock Based Compensation Chart

Biocept Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Stock Based Compensation

Get a 7-Day Free Trial

0.55

0.78

0.77

2.18

3.05

Biocept Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Stock Based Compensation	Get a 7-Day Free Trial															0.56	0.47	0.40	0.30	0.19

Biocept Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.35 Mil.

Biocept Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Biocept's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocept (FRA:B00) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (FRA:B00) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

BIOCQ:USA

Address

9955 Mesa Rim Road, San Diego, CA, USA, 92121

Website

https://www.biocept.com

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept (FRA:B00) Headlines

No Headlines